A Randomized Prospective Trial of Conversion to Everolimus Therapy From Calcineurin Inhibitor Based Maintenance Immunosuppression in Association With Mycophenolic Acid in Liver Transplantation: Examination of Impact on Long Term Renal Function.
Phase: NA
Conditions: Immunosuppression, Renal Failure
Sponsor: Milton S. Hershey Medical Center

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 1 of 18
Title: A Randomized Prospective Trial of Conversion to Everolimus 
Therapy from Calcineurin Inhibitor Based Maintenance 
Immunosuppression in association with Mycophenolic Acid in Liver 
Transplantation:  Examination of Impact on Long Term Renal 
Function (December 28, 2018)
Principal Investigator: Zakiyah Kadry MD                     
Dept./Div:  Transplant Division/ Department of 
Surgery
___________________________
Zakiyah Kadry, MD                                Date
Chief, Division of Transplant Surgery
Professor of Surgery
The Penn State Milton S. Hershey Medical Center
500 University Drive; MC: H062
Hershey, PA  17033
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 2 of 18
Table of Contents
Sections
1.0
Introduction
2.0
Objectives
3.0
Study Design and Methods
4.0
Inclusion and Exclusion Criteria
5.0
Recruitment and Consent Process
6.0
Study Procedures
7.0
Risks and Discomforts
8.0
Benefits
9.0
Reporting of Adverse Events and Unanticipated Problems Involving Risks to 
Participants or Others
10.0
Study Withdrawal/Discontinuation
11.0
Statistical Analysis of the Study
12.0
Privacy and Confidentiality Considerations
13.0
Data and Safety Monitoring Plan
14.0
Compensation
15.0
Drugs, Biologics, or Devices
16.0
Records and Study Monitoring
17.0
Facilities
18.0
References
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 3 of 18
1.0
Introduction
Post liver transplant maintenance immunosuppression is based on calcineurin inhibitors, which have a 
nephrotoxic effect. Calcineurin inhibitors cause microvascular and glomerular damage and are associated 
with arteriolar hyalinosis and striped interstitial fibrosis of the kidneys.  Early calcineurin inhibitor related 
changes may be reversible but nephrotoxicity with chronic administration of these immunosuppressant 
agents appears to be irreversible and can sometimes lead to renal transplantation. Significant renal 
impairment has been observed in 27% of liver transplant recipients at 5 years postoperatively, with up to 
10% reaching end stage renal disease.  Such late chronic renal failure has been associated with a 
significant risk of premature death and can be predicted by creatinine levels in the first year post liver 
transplant.  With the implementation of the MELD (Model for End Stage Liver Disease) liver allocation 
system, more patients are reaching liver transplantation with baseline renal dysfunction as creatinine is 
heavily weighted within the MELD score.  
Everolimus is a macrolide immunosuppressant of the proliferation signal inhibitor class (PSI, mTOR 
inhibitor).  It is an orally active 40-O-(2-hydroxyethyl) derivative of sirolimus, which blocks growth factor-
dependent cellular proliferation through a calcium independent signal.  The immunosuppressive effect of 
everolimus is exerted by blocking interleukin 2 and interleukin 15 driven proliferation of hematopoietic (T 
& B cells) and non hematopoietic (vascular smooth muscle cells) cells by inhibiting the activation of 
p70S6 kinase.  This arrests the cell cycle at the G1 phase thus preventing the progression into the S 
phase.  Both everolimus exerts its inhibitory effect by forming a complex with the immunophilin FK506 
binding protein 12.  The 50% inhibitory concentration for everolimus inhibition of FK506 binding to FK506 
binding protein 12 is 1.8 to 2.6 nmol/L which is approximately 3x higher than that of sirolimus (0.4-0.9 
nmol/L). 
Interest in mTOR inhibitors, such as everolimus, lies in their potential renal sparing effect in the setting of 
calcineurin inhibitor maintenance therapy in heart, renal and liver transplantation.  Everolimus as the 
newer of the mTOR inhibitor agents has the advantage of a shorter half life (40 hrs), allowing a once daily 
oral administration. Data showing improvement of renal function when an mTOR inhibitor completely 
replaces a calcineurin inhibitor in renal transplantation makes such a strategy particularly attractive as a 
renal sparing immunosuppressive regimen for liver transplant recipients.
A high proportion of liver transplant candidates on the Penn State Hershey Medical Center waiting list are 
in renal failure at the time of liver transplant.  From September 2005 until January 2011, a total of 111 
orthotopic liver transplants were performed.  Forty three (39%) of these recipients showed evidence of 
renal failure in the pre- transplant period with a creatinine level > 2mg/dL.  Fifteen patients required intra-
operative continuous venovenous hemodiafiltration (CVVHD), 8 required CVVHD pre-transplant and five 
underwent dialysis in the post transplant period.  The predominant cause of renal failure in these patients 
was hepatorenal syndrome with a prolonged course in some patients due to the long waiting time and 
organ donor shortage.  The postoperative immunosuppressive protocol implemented at Penn State 
consists of a combination of a calcineurin inhibitor (tacrolimus or cyclosporine), mycophenolic acid and 
steroids (tapered over the first 3 months). 
Given the increasing proportion of patients having renal failure at the time of transplant, associated with the 
nephrotoxic effect of calcineurin inhibitor based immunosuppression associated with its long term negative 
survival impact, this study proposes to examine the renal sparing impact of conversion to everolimus from 
a calcineurin inhibitor based immunosuppressive protocol between 90 days -120 days post liver transplant.  
90 days-120 days  post transplant was chosen to allow for the switch to everolimus to occur at a period of 
stable post transplant liver function when both technical and rejection risks are lower.  The 90 days-120 
days  was also chosen because of data indicating that worsening renal function at 4 weeks, 3 months and 
1 year post transplant is an independent risk factor for the development of chronic renal failure and end 
stage renal disease after orthotopic liver transplantation. 
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 4 of 18
2.0  
Objectives
Primary:  
Examine the renal sparing impact of implementing a strategy of conversion to everolimus from a 
calcineurin inhibitor based immunosuppressive protocol between 90 days-120 days post liver 
transplant.
Secondary:
-
Evaluate patient and liver graft survival at 6, 12, and 24 months.
-
Evaluate incidence and severity of biopsy proven rejection at 6, 12, and 24 months.
-
Evaluate the cost-effectiveness of the strategy of conversion to everolimus from calcineurin inhibitor 
between 90 days-120 days post liver transplant.
-
Perform recipient and donor genotyping to examine their impact on optimizing the dosage of 
everolimus. 
3.0
Study Design and Methods
-
This is a prospective randomized open label pilot study to assess superiority of 
immunosuppressive regimen.  Patients will be randomized to one of two arms between 90 
days-120 days post transplant:  
-
Arm A:  Conversion to Everolimus immunosuppression combined with mycophenolic acid 
(Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor will occur after the target 
level of Everolimus is reached. .
-
Arm B:  Continuation with standard immunosuppressive therapy consisting of Calcineurin 
inhibitor associated with mycophenolic acid (Myfortic: MPA).
-
Steroids are routinely discontinued at 3 months post transplant as part of the Penn State 
standard immunosuppressive protocol (Exceptions to steroid discontinuation: Primary 
diagnosis of autoimmune cirrhosis, primary biliary cirrhosis and primary sclerosing cholangitis).  
-
Recipients of a deceased donor liver transplant who are 18-70 years of age will be asked 
between 90 days -120 days post transplant whether they wish to participate in this study.
-
4.0
Inclusion and Exclusion Criteria
Study Population:  This will be a pilot study which will include 12 adult deceased donor liver transplant 
recipients in each study arm.  
Inclusion

Ability and willingness to provide written informed consent and adhere to study regimen.
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 5 of 18

Recipients who are 18-70 years of age of a primary liver transplant from a deceased donor.

Allograft is functioning at an acceptable level by the time of randomization as defined by the AST, 
ALT, Total Bilirubin levels ≤3 times ULN, and AlkP and GGT levels ≤ 5 times ULN. Elevated GGT 
alone, in combination with AST, ALT, total bilirubin and AlkP within the defined range does not 
exclude patients from randomization.

Recipients who have been initiated on an immunosuppressive regimen that contains 
corticosteroids and tacrolimus or cyclosporine by 7 days post-transplantation.

Confirmed recipient HCV status at Screening (either by serology or by PCR). Laboratory results 
obtained within 12 months of screening are acceptable.

Abbreviated MDRD eGFR ≥ 30 mL/min/1.73m2. Local and central serum creatinine results 
obtained within 5 days prior to randomization are acceptable, however no sooner than Day 25 
post-transplantation.

Verification of at least one tacrolimus trough level of ≥ 8 ng/mL in the week prior to randomization. 
Investigators should make adjustments in tacrolimus dosing to continue to target trough levels 
above 8 ng/mL prior to randomization.

Patients who are able to take oral medication at time of randomization.
Exclusion

Patients who are recipients of multiple solid organ or islet cell tissue transplants, or have 
previously received an organ or tissue transplant. Patients who have a combined liver kidney 
transplant.

Recipients of a liver from a living donor, or of a split liver.

History of malignancy of any organ system within the past 5 years whether or not there is 
evidence of local recurrence or metastases, other than non-metastatic basal or squamous cell 
carcinoma of the skin or HCC (see next criteria).

Hepatocellular carcinoma that does not fulfill Milan criteria (1 nodule ≤ 5 cm, 2-3 nodules all < 3 
cm, seen at the time of transplantation as per explant histology of the recipient liver.

Any use of antibody induction therapy.

Patients with a known hypersensitivity to the drugs used on study or their class, or to any of the 
excipients.

Patients who are recipients of ABO incompatible transplant grafts.

Recipients of organs from donors who test positive for Hepatitis B surface antigen or HIV are 
excluded.

Patients who have any surgical or medical condition, which in the opinion of the investigator, 
might significantly alter the absorption, distribution, metabolism and excretion of study drug.

Women of child-bearing potential (WOCBP), defined as all women physiologically capable of 
becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes 
intercourse with a male partner and women whose partners have been sterilized by vasectomy or 
other means, UNLESS (1) they meet the following definition of post-menopausal: 12 months of 
natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH 
levels >40 mIU/m, or (2) have past 6 weeks from surgical bilateral oophorectomy with or without 
hysterectomy or (3) are using one or more of the following acceptable methods of contraception: 
surgical sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception 
(implantable, patch, oral), copper coated IUD and double-barrier methods ( any double 
combination of male or female condom with spermicidal gel, diaphragm, sponge, cervical cap). 
Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and 
withdrawal are not acceptable methods of contraception. Reliable contraception should be 
maintained throughout and for 3 months after study drug discontinuation.
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 6 of 18

Patients with any history of coagulopathy or medical condition requiring long-term anticoagulation 
which would preclude liver biopsy after transplantation. (Low dose aspirin treatment or 
interruption of chronic anticoagulant is allowed).
Enrollment Exclusion - Randomization

Patients who have severe hypercholesterolemia (>350 mg/dL; >9 mmol/L) or hypertriglyceridemia 
(>500 mg/dL; >8.5 mmol/L) within 6 months of transplantation. Patients with controlled 
hyperlipidemia are acceptable at the time of randomization.

Patients with platelet count < 50,000/mm3 at the time of randomization.

Patients with an absolute neutrophil count of < 1,000/mm³ or white blood cell count of 
<2,000/mm³ at the time of randomization.

Patients who have tested positive for HIV. Negative laboratory results obtained within 6 months 
prior to transplant are acceptable.

Patients with clinically significant systemic infection requiring active use of IV antibiotics at the 
time of randomization. Patients who are in a critical care setting at the time of randomization 
requiring life support measures such as mechanical ventilation, dialysis, requirement of 
vasopressor agents.

Patients who require renal replacement therapy for clearance within 7 days prior to 
randomization.

The presence of thrombosis via Doppler ultrasound of the major hepatic arteries, major hepatic 
veins, portal vein and inferior vena cava. Results obtained within 5 days prior to randomization 
are acceptable, however no sooner than Day 25 post-transplantation. 

An episode of acute rejection that required antibody therapy or more than one steroid sensitive 
episode of acute rejection during the run-in period. This includes patients who have not 
completed steroid treatment for acute rejection within 7 days prior to randomization.

Patients with a confirmed spot urine protein-to-creatinine ratio that indicates greater than 0.7 mg 
protein /mg creatinine.  Laboratory results obtained after transplant surgery and within 4 months 
of randomization are acceptable.  

Use of immunosuppressive agents or treatments after baseline that are not utilized in the 
protocol.
5.0
Recruitment and Consent Process
The primary investigator, Dr Zakiyah Kadry, will obtain consent and discuss in detail the process of 
randomization and the risks and benefits of the study both at time of admission for transplant and 
between 90 days-120 days post-operatively.  Patients will be provided with a copy of the consent form at 
time of transplant to allow them to consider participation in the study between 90 day-120 day time point.  
Patients will also be seen regularly on an outpatient basis for routine follow up in the first 3 months of 
transplant, at which point any additional questions they may have about the study can be addressed.  
Between 90 days-120 days post transplant, patients will be seen on an outpatient basis and will be asked 
if they are interested in participation, during which time the study randomization process and consent 
process will again be undertaken in detail. 
6.0
Study Procedures
Conversion from CNI to Everolimus in Arm A:
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 7 of 18
Randomization will only occur between 90days and 120 days post transplant.  Patients randomized 
between 90 days and 120 days for conversion to Everolimus, in association with Mycophenolic acid, will 
start Everolimus at a dose of 0.75mg twice daily, with target levels at 3 to 8 ng/mL.  Blood levels of 
Everolimus will be measured by the FDA approved assay by ThermoFisher.  The calcineurin inhibitor 
(tacrolimus or cyclosporine) will be withdrawn after the target levels of Everolimus are reached.Concurrent 
immunosuppression with MPA will be maintained in both arms with dosage dependant on the degree of 
bone marrow suppression and leucopenia. 
The calcineurin inhibitor (tacrolimus or cyclosporine) will be withdrawn after the target level of Everolimus 
is reached. 
For Tacrolimus:  After everolimus blood trough levels have been confirmed to be in the target range (3-8 
ng/mL), tacrolimus tapering will begin, targeting a tacrolimus whole blood trough level of 3-5 ng/mL by three 
weeks after randomization. Once that point is reached  tacrolimus elimination will begin while maintaining 
everolimus whole blood trough levels within the target range of 6-8 ng/mL. 
For Cyclosporine:  After everolimus blood trough levels have been confirmed to be in the target range (3-8 
ng/mL), cyclosporine tapering will begin, targeting a cyclosporine whole blood trough level of 50 to 100 
ng/mL by three weeks after randomization. Once that point is reached cyclosporine elimination will begin 
while maintaining everolimus whole blood trough levels within the target range of 6-8 ng/mL.
Prior to CNI elimination, the inclusion criteria for liver function tests will be re-applied. If a patient does not 
exhibit a functioning allograft at an acceptable level by as defined by the AST, ALT, Total Bilirubin levels 
being  ≤3 times the upper limits of the normal values (ULN) and Alkaline Phosphatase and Gamma Glutamyl 
Transferase levels ≤5 times ULN, then the patient will be monitored until these criteria are met, after which 
tacrolimus/cyclosporine elimination can begin.
Everolimus and CNI trough concentrations will be measured twice a week for the first 6 months after 
transplant.  After 6 months, trough concentrations may be measured on a weekly basis until end of month 
12 post transplant, after which levels maybe measured on a q2weekly basis.  Patients seen in the post liver 
transplant clinic may have an additional measurement performed that day in conjunction with their routine 
laboratory work.  
Target levels for Arm B:
The most common CNI used at our institution is prograf (Tacrolimus) & at 3 months the level is maintained 
at 10-12 ng/mL unless the patient has hepatitis C where the levels are kept at a slightly lower level of 8-10 
ng/mL. Concurrent immunosuppression with MPA will be maintained in arm B with dosage dependant on 
the degree of bone marrow suppression and leucopenia.  If cyclosporine is utilized, the level at 3 months is 
maintained at the 200 to 250 ng/mL range unless the patient has hepatitis C where the levels are kept at a 
slightly lower level of 150 to 200 ng/mL. 
Study duration:  
Start Date: 1 October 2012
End Date: 1 October 2019
2 year subject enrollment..
Evaluation schedule:  
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 8 of 18
Visit number
1
Screening*
2
Baseline*
3
4
5
Time of Visit
90days-120 
days post 
transplant
90days-
120 days 
post 
transplan
t
Month 6 
+/- 2 
weeks***
Month 12+/- 
2 weeks ***
Month 
24+/-2 
weeks ***
Inclusion/Exclusion criteria
X
x
Informed consent
X
Physical 
examination(medical history 
and vital signs
X
x
x
x
x
Clinical assessment 
X
x
x
x
x
Quality of Life 
Questionnaires
(FACT-Hep; EQ-5D)
X
X
X
X
X
Dispense study medication
x
Return study medication
x
Laboratory test  (blood & 
urine collection)
X
x
x
x
x
Adverse events
x
x
x
x
Blood test-HIV, hepatitis 
viruses, CMV and 
genotyping
X
Pregnancy Test
X
Concomitant Medications 
(Standard of Care) **
Valcyte                                      
Bactrim(PCP prophylaxis)
Mycophenolic acid (Myfortic)
X
X
X
X
X
X
X
X
X
X
X
* If the patient meets all inclusion criteria at the Screening Visit, the Screening and Baseline visits may occur on the same 
day and will occur between 90 days and 120 days post transplant.
**All patients receive CMV prophylaxis with Valcyte in the 1st 4 postoperative months as part of standard care.  Bactrim 
prophylaxis against Pneumocystis carinii is administered for the first year post transplant as part of standard care.  Steroids 
are discontinued at 3 months post-transplant while Myfortic is continued as part of the maintenance immunosuppressive 
protocol.
***Visit window for follow up visits at months 6, 12 and 24 is plus or minus 2 weeks
Tests at above evaluation schedule:  
  
a.
Renal function as assessed by the iothalamate clearance test starting at Baseline visit.
b.
Renal Function as assessed by serum creatinine, by Cockcroft-Gault formula mL/min, and 24 
hour urine collection for creatinine clearance and urinary protein level starting at Baseline visit.  
c.
Liver Recipient blood sample for genotype testing.
d.   Testosterone levels
The genetic tests will involve TaqMan real-time PCR of extracted DNA, and subsequent identification 
of alleles associated with investigated polymorphic SNP  by means of allele-specific 5’ nuclease 
assay, using the pre-developed assay and Custom TaqMan® SNP Genotyping reagents for allelic 
discrimination by TaqMan real-time PCR on AbiPrism 7900HT Sequence Detection System (Applied 
Biosystems, Foster City, CA). The above will involve following genes and polymorphisms: CYP3A5 
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 9 of 18
gene:  6986 A>G (alleles *1 and *3) and ABCB1 (MDR1) exon26 (3435C>T) and exon21 
(2677G>T/A).
7.0
Risks and Discomforts
The following adverse reactions have been described with everolimus: Leukopenia, the development of 
increased cholesterol and hyperlipidemia (high blood fats) levels, thrombocytopenia, anemia and a 
predisposition for viral, bacterial and fungal infections due to the immunosuppressant effect of everolimus. 
Hemolytic uremic syndrome, surgical wound complications, venous thromboembolism, acne and 
hypertriglyceridemia have also been described. Additional common side effects observed in transplant 
patients taking everolimus include hypertension, gastrointestinal disorders and edema.  In two adult 
kidney transplant studies, less than 5% of the patients exhibited the combination of low testosterone and 
sexual dysfunction as an adverse event.  However, the clinical implications of this are not clear.
Side effects of calcineurin inhibitors such as tacrolimus and cyclosporine are well described and include 
nephrotoxicity, neurotoxicity, hyperkalemia, and hypomagnesemia.  Cyclosporine also causes 
hypertension, hepatotoxicity, hirsutism, hypertension, hyperlipidemia, gingival hyperplasia and sinus 
congestion.  Unlike cyclosporine, Tacrolimus causes alopecia, may have a diabetogenic effect and 
causes less disturbances in lipid metabolism. Allergic reactions can occur with tacrolimus depending on 
the formulation, especially if castor oil is used.
Side effects of Iothalamate clearance test:
Rare allergic reactions to iothalamate in subjects known to be allergic to iodine.  Can range from urticaria 
to anaphylactic shock.  Other adverse effects of iothalamate include arrythmias, bradycardia, generalized 
vasodilation, extravasation of iothalamate during injection, seizures, and weakness of extremities.  
Abnormal sensation or muscle spasm in the injection site has been reported but in patients being infused 
with five to thirteen times the amount planned in this study and at a faster infusion rate.
  
Mycophenolic acid has bone marrow suppression as the main side effect and rarely may have 
neurotoxicity associated with it.  It is also an enteric coated formulation and hence should have less of the 
GI side effects such as nausea, vomiting and diarrhea, than mycophenolic mofetil which is a similar drug.
Given that arm A will consist of the patients on everolimus and mycophenolic acid, with complete withdrawal 
of calcineurin inhibitor, there will be a risk of bone marrow suppression and leucopenia, which will be dosage 
dependant.
Both calcineurin inhibitors and mycophenolic acid increase the patient risk for cancer, especially post 
transplant lymphoproliferative disease.   Everolimus is thought to have an antiproliferative effect and may 
reduce the risk for the development of cancer.   
All patients will be monitored closely for any of the above side effects.  Other than the scheduled study 
clinic visits and testing, allpatients will be followed as per the Penn State Division of Transplantation 
follow up guidelines. For the first 24 months post liver transplant all our patients undergo the following 
routine lab collection procedure, the frequency of which may be adjusted based on patient clinical status 
and need:
 Routine/standard of care laboratory tests from post op month 1 through post op month 24 include: : 

1st 5 months postop: 2x/week labs as follows:   Sodium, Potassium, Chloride, Bicarbonate level, 
BUN, Creatinine, Magnesium, Calcium, Phosphorus, CBC, PT, INR, PTT, Liver Function Tests 
(Total & Direct Bilirubin, AST, ALT, Alkaline Phosphatase & Gamma Glutamyl Transferase), 
Glucose & Immunosuppressive agent trough levels. Lipid Panel to be performed once a week.  
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 10 of 18

Month 6 to 12 inclusive: q weekly labs: Sodium, Potassium, Chloride, Bicarbonate level, BUN, 
Creatinine, Magnesium, Calcium, Phosphorus, CBC, PT, INR, PTT, Liver Function Tests (Total & 
Direct Bilirubin, AST, ALT, Alkaline Phosphatase & Gamma Glutamyl Transferase), Glucose,  
Immunosuppressive agent trough levels and Lipid Panel.

After month 12: q2weekly labs: Sodium, Potassium, Chloride, Bicarbonate level, BUN, Creatinine, 
Magnesium, Calcium, Phosphorus, CBC, PT, INR, PTT, Liver Function Tests (Total & Direct 
Bilirubin, AST, ALT, Alkaline Phosphatase & Gamma Glutamyl Transferase), Glucose,  
Immunosuppressive agent trough levels and Lipid Panel.
Any abnormal laboratory values routinely result in a complete evaluation of the patient which may also 
include radiologic studies and a liver biopsy.  Dose adjustments &/or discontinuation of medications may 
be required.
Years 2 & 3 Post Liver Transplant:
At 24 months post transplant patient’s will have their final study visit and will be followed by the Divisions 
of Tranplant and Hepatology per standard of care. Labwork includes: Sodium, Potassium, Chloride, 
Bicarbonate level, BUN, Creatinine, Magnesium, Calcium, Phosphorus, CBC, PT, INR, PTT, Liver 
Function Tests (Total & Direct Bilirubin, AST, ALT, Alkaline Phosphatase & Gamma Glutamyl 
Transferase), serum Glucose, Immunosuppressive agent trough levels and Lipid Panel. 
Clinic Visits:
Year 1: 
1x/week x 1 month
Every 2 weeks x 1 month
If stable: clinic visit x 1 at 1, 3, 6 & 9 months
Any persistent elevation in liver function tests (on consecutive testing within 1 week) or clinical issues: 
patient is brought to clinic regardless of scheduled clinic visits.
Years 2 & 3 inclusive:
Clinic every 3 months, unless elevation in liver function tests (persistent on 2 consecutive tests over a 1 
week period) or if medication change or if clinical symptoms/complaints. If the latter occurs, patients 
should be seen in clinic during that week.
All patients undergo a full history and physical examination during their clinic visit associated with a 
complete review of their laboratory results and their current medications.  
In this study, patients will be monitored for the development of medication side effects:
Everolimus & Mycophenolic Acid: 
For patients who are unable to tolerate the protocol-specified dosing schedule of everolimus, dose
adjustments will be made according to the following guidelines:
The everolimus dose will be decreased by at least 0.25 mg b.i.d if a dose reduction is necessary. If a 
temporary reduction in everolimus level is needed, the everolimus trough blood level will be maintained 
no lower than 3 ng/mL.   Everolimus will be discontinued if a trough level ≥ 3 ng/mL cannot be maintained 
due to toxicity. Severe and unremitting changes/side effects may also lead to everolimus discontinuation.
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 11 of 18
If everolimus is interrupted for safety reasons for longer than 21 consecutive days, or for more
than 2 episodes of 7 days or longer, discontinuation of study medication will be maintained and the 
patient will be removed from the study. 
During the course of the trial everolimus will be administered on a b.i.d. regimen.  Everolimus will not be 
provided to patients after they have discontinued the study.
If reduction of everolimus is necessary for the patient to remain in target trough range, everolimus dosing 
will be reduced by 0.25 mg intervals.
In cases of hyperlipidemia, lipid lowering therapy will be optimized before dosage reduction of study 
medication is considered.  Patients will be managed with HMG Co-A reductase inhibitors (e.g., 
fluvastatin). Lovastatin or simvastatin will not be utilized. The starting dose of HMG Co-A reductase 
inhibitors will be equivalent to 20 mg pravastatin or 20 mg fluvastatin, and may be increased to target with 
the aim of maintaining a LDL level of < 130 mg/dL.   Patients will be monitored for the development of 
rhabdomyolysis or other adverse events.
Both everolimus and mycophenolic acid have a bone marrow suppressant effect and predispose patients 
to neutropenia.  Patients who develop neutropenia with an absolute neutrophil count (ANC) <1000 will be 
initially treated with administration of neupogen (filgrastim) at a dose of 5mcg/kg/day subcutaneously prior 
to dose reduction of immunosuppressant agents. If there is no response to neupogen therapy after 3 
consecutive treatment days, dose reduction of mycophenolic acid will first be undertaken.  If the ANC 
persists at <1000 after reduction of mycophenolic acid, a dose reduction in everolimus should be 
undertaken as outlined below. .
Guidelines for everolimus dose reduction/interruption:
Platelet count 
(/mm3)
Hemoglobin
(g/dL)
ANC count
(K/Ul)
Cholesterol
(mmol/L)
Triglycerides
(mmol/L)
Dose reduction
≤ 75,000
≤ 8
≤ 1000
≥ 8
≥ 6.5
Interruption
≤ 50,000
≤ 6
≤ 500
≥ 9
≥ 8.5
All patients will be carefully assessed for any of the side effects or adverse reactions related to 
everolimus through a detailed history and physical examination during clinic visits as listed above and 
through a thorough and complete examination of their routine and study laboratory values.  
A foley catheter placement is required during iothalomate testing to accurately measure urine output 
collection.  Risks of foley catheter placement include: pain, hematuria, injury to urethra, urinary retention 
following removal of foley, urinary tract infection and bladder spasms. 
Patients will be withdrawn from the study in the event of a serious life threatening adverse event. 
 
8.0
Benefits
Everolimus has a profile of anti-lymphoproliferative and anti-angiogenic effects in addition to its 
immunosuppressant effects and lacks nephrotoxicity.  The main benefit of this study relates to renal 
sparing in patients in arm A, who will be converted  from a calcineurin based immunosuppressive protocol 
to everolimus in combination with mycophenolic acid between 90 days-120 days post operatively.  Thus 
the main benefit which is being evaluated in this study will be improvement and stability in renal function 
compared to patients on long term calcineurin inhibitors, which in the long run is believed to result in 
better long term survival outcomes. 
9.0 
Reporting of Adverse Events and Unanticipated Problems Involving Risks 
to Participants or Others
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 12 of 18
All adverse events (AE) will be documented on study specific case report forms and entered into a computer 
based log.  All deaths on study, not related to progression of underlying disease, will be reported to the IRB 
and study sponsor immediately.  All unanticipated AEs related or possibly related to the study will be 
reported by the PI to the IRB according to HSPO policies and procedures.
10.0
Study Withdrawal/Discontinuation: 
This is a small pilot study (12 randomized patients in each of two groups) and in view of the small 
patient cohort. Stopping rules for this study will therefore be based on patient safety.
  
Monitoring Process: 
Primary monitoring of the study will be performed by the study team, who will review accrual, 
adverse events, and dose limiting toxicities on a real-time basis.  Cumulative adverse events and 
study toxicities will be reviewed weekly.  The study team will make decisions regarding dose 
escalation, cessation of accrual, and whether stopping rules have been reached.  A Data Safety 
Monitoring Board (DSMB) has been created and its members are listed in the study protocol at 
the end of Section 13.  The DSMB will review the study progress reports provided to the DSMB 
by the study team and a statistician.  A DSMB report will be generated by the DSMB and 
forwarded to the IRB and the PI.  A copy of any interim DSMB reports will be included with 
continuing review reports submitted by the PI for IRB review.
 
If stopping rules have been reached, this will be communicated to the IRB immediately.
Serious adverse events that would qualify for patient removal from study would include:
-
Refractory leucopenia ≤ 500 unresponsive to drug dose reduction/interruption or stimulation by 
Neupogen (filgrastim).
-
Persistant thrombocytopenia at <50,000/mm3, unresponsive to study medication dose 
reduction/interruption.
-
Refractory hyperlipidemia (Cholesterol ≥ 9 mmol/L or Triglycerides ≥ 8.5 mmol/L ) unresponsive 
to treatment (as outlined in section 7 of the protocol) and to study medication dose 
reduction/interruption.
-
Refractory anemia (Hemoglobin ≤ 6 g/dL) not related to surgical bleeding, and unresponsive to 
blood transfusion and to study medication dose reduction/interruption.  
-
Development of hemolytic uremic syndrome
-
Development of any thrombotic events such as liver graft hepatic arterial or portal/hepatic venous 
thrombosis, or thrombotic microangiopathy or thrombotic thrombocytopenic purpura, or 
radiologically documented pulmonary embolism.
-
Refractory seizures or neurologic side effects unresponsive to treatment or reduction/interruption 
of study medication.
-
Life threatening infectious complications.
Reasons for discontinuation of the study drug everolimus will include:
∙ AE(s)
∙ Abnormal laboratory value(s)
∙ Abnormal test procedure result(s)
∙ Unsatisfactory therapeutic effect
∙ Significant protocol deviation
∙ Withdrawal of consent
∙ Lost to follow-up
∙ Death
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 13 of 18
∙ Graft Loss/Re-transplant
Premature Patient withdrawal:
Patients may voluntarily withdraw from the study or be dropped from it at the discretion of the investigator 
at any time. Patients will be withdrawn from the study if any of the following occur:
•
Withdrawal of consent
•
Lost-to follow-up
•
Graft loss/re-transplant
•
Death
•
Serious life threatening adverse event.
If such withdrawal occurs, or if the patient fails to return for visits, the primary reason for a patient’s 
premature withdrawal from the study will be recorded.
For patients who are lost to follow-up, "due diligence" will be shown by documenting in the patient record 
steps taken to contact the patient, e.g. dates of telephone calls, registered letters, etc.
Patients who are prematurely withdrawn from study medication or from the study after  randomization  will 
not be replaced. Patients who withdraw or screen fail prior to randomization will be replaced.  
 
Patients who prematurely discontinue everolimus will be followed for any SAE occurring
within 30 days following the last dose of everolimus. These SAEs will be reported on the
SAE form.
 
Patients who become pregnant while taking everolimus or are taking a prohibited
immunosuppressive medication not allowed by the protocol will be discontinued from the
investigational drug and from the study.
If the everolimus trough level ≥ 3 ng/mL cannot be maintained, patients will be discontinued from the 
study.
11.0
Statistical Analysis of the Study
The primary endpoint of the trial is a renal function as assessed by 24 hour creatinine 
clearance.  
We will compare creatinine clearance between the two arms of the study using a t-test.  We expect that 
due to randomization there will be no differences in baseline characteristics of the two groups, so no 
multivariate analyses are planned.  However, if we find significant difference between the two groups in 
such variables as demographics or disease characteristics, we will control for these variables in a linear 
regression analysis.  In addition, we will also explore the use of nonparametric tests (i.e. Mann-Whitney U 
test for renal function) because of the relatively small sample size.
Secondary endpoints will also be tested using univariate statistical tests.  The presence of acute rejection 
will be compared between study arms using chi-square tests.  We will also fit nonparametric survival models 
to the time to acute rejection to determine whether rejection occurs earlier or later between study arms.  
Patient and graft survival will be modeled using Kaplan-Meier curves, with comparisons made between 
arms using the log rank test.  To study the effect of donor and recipient genotype testing on postoperative 
renal function we will study the interaction between treatment arm and presence of CYP3A and P-gp SNPs 
on creatinine clearance.  This will be done using a one-way analysis of variance with main effects for 
treatment and SNPs, and interaction terms between treatment and the SNPs.  
Safety endpoints are all binary indicators (discontinuation, change of therapy, hyperlipidemia, etc.).  All of 
these safety endpoints will be compared between treatment arms using chi-square tests.
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 14 of 18
We will use the clinical trial data to determine whether the everolimus approach is cost-effective relative to 
the calcineurin inhibitor based regimen.  Costs will be estimated from the perspective of the provider and 
the time horizon will cover the period of the trial.  Costs will be obtained from the hospital’s cost-accounting 
database and will include fixed and variable direct medical costs.  Our effectiveness measure for the base 
case analysis will be renal function either as a continuous measure or in categorical increments (e.g. 5 or 
10 ml/min).  As a secondary measure of effectiveness we may also study life years gained (YLG), but only 
if substantial differences are observed in the sample.  This will be estimated by the area under the survivor 
functions for each treatment arm. 
Cost-effectiveness analysis asks whether one intervention provides value for resources expended 
compared to another intervention and is appropriate when alternative interventions have differing 
implications for costs and patient outcomes.  The cost-effectiveness of the everolimus strategy will be 
summarized with an incremental cost-effectiveness ratio (ICER).  
(1)
ICER Ce Cci
Ee Eci
where Ce the cost of the everolimus strategy, Cic is the cost of the calcineurin inhibitor strategy, Ee is the 
effectiveness of the everolimus strategy, and Eci is the effectiveness of the calcineurin inhibitor strategy.  
Although we are interested in YLG gained as a measure of effectiveness it is not likely that with 24 patients 
the difference will be substantial enough to use.  Therefore, our primary measure of effectiveness will be 
units of improvement in renal function.  As a secondary measure we will use YLG if large enough differences 
are observed in our sample.  The ICER represents the incremental cost required to achieve one additional 
unit of benefit if patients are transtioned from cacineurin inhibitors to everolimus.  The uncertainty 
surrounding the ICER estimates will be quantified by bootstrapping our cost and effectiveness data to form 
95% ellipses around the cost-effectiveness ratio[25-27].  We will also estimate cost-effectiveness 
acceptability curves to show how the likelihood of cost-effectiveness varies with the willingness to pay of 
the decision maker [28].
For all statistical analyses we will define significance as p-values less than 0.05.  If multiple comparisons 
are required (for example, to study the same variable at difference time points) then we will adjust the p-
values using a Bonferroni correction.
Sample size and power:  
The study was powered to measure significant improvements in renal function.  To estimate the required 
sample size we assumed that the estimated glomerular filtration rate (eGFR) would improve from 34 
mL/min/1.73 m2 to 43 mL/min/1.73 m2 as reported in a recent study by Fairbanks et al [29].   This is a 
conservative estimate since the renal sparing effects of everolimus are larger than those of sirolimus.  A 
sample size of 12 in each group will have 80% power to detect a difference in means of -9.0 (the difference 
between a Group 1 mean of 34.0 and a Group 2 mean of 43.0) assuming that the common standard 
deviation is 7.5 using a two group t-test with a 0.050 two-sided significance level.  Fairbanks did not report 
standard deviations for eGFR, however, a simulation study suggests that the standard deviation at baseline 
was 7.5, and the standard deviation following conversion was 16.  We therefore, considered the sample 
size requirement for a range of standard deviations, shown in the Figure below.  If the common standard 
deviation was 16, then 51 patients per group would be required to detect a significant difference of 9.0 with 
80% power.  This sample size may not be feasible for a pilot study such as this.  However, 12 per group is 
feasible and can be justified by the lower limit of standard deviation reported in Fairbanks.
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 15 of 18
0
5
10
15
20
25
0
10
20
30
40
50
60
70
80
90
Standard Deviation
N Per Group
12.0
Privacy and Confidentiality Considerations
All data forms and study specific information will be kept in locked file cabinets and in a password protected 
computer database with access limited to the PI, clinical research nurses, and sponsor designees.  Any 
presentation or publication of the data will be done in aggregate fashion without identifiers.
A Data Safety Monitoring Board (DSMB) will review the study progress reports provided to the DSMB by 
the study team and statistician.  A DSMB report will be generated by the DSMB and forwarded to the IRB 
and the PI.  A copy of any interim DSMB reports will be included with continuing review reports submitted 
by the PI for IRB review.  
13.0
Data and Safety Monitoring Plan:
This study is a prospective randomized open label pilot study examining the impact of conversion to 
everolimus therapy from standard calcineurin inhibitor immunosuppression.  Oversight for the conduct of 
the study will be provided by the PI, Zakiyah Kadry MD, and the clinical research nurse.  They will ensure 
that all eligibility and consent requirements are met prior to a subject’s participation on study and that all 
study procedures and adverse event reporting occur according to the IRB approved protocol. They will 
follow all study participants, while on study treatment, on a real-time basis for development of adverse 
events and study end points, utilizing scheduled and as needed physical examinations and laboratory 
studies.  They will make certain that all adverse events are recorded and reported according to the Penn 
State HSPO (Human Subjects Protection Office) guidelines and that the IRB is notified in a timely manner 
of any significant safety or data concerns which arise from study review.
Primary monitoring of the study will be performed by the study team, who will review accrual, adverse 
events, and dose limiting toxicities on a real-time basis.  Cumulative adverse events and study toxicities 
will be reviewed weekly.  The study team will make decisions regarding dose escalation, and cessation of 
accrual.
A Data Safety Monitoring Board (DSMB) will review the study progress reports at six month intervals, with 
study progress reports provided to the DSMB by the study team and statistician.  A DSMB report will be 
generated by the DSMB and forwarded to the IRB and the PI.  A copy of any interim DSMB reports will be 
included with continuing review reports submitted by the PI for IRB review. 
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 16 of 18
 
14.0
Compensation
For patients randomized into Group A who are receiving Everolimus medication will be 
reimbursed for travel expenses in order to return twice per week during the first 3 months after 
randomization to have the Everolimus blood level checked at Hershey Medical Center’s 
Laboratory.  The reimbursement for travel expense is 24 cents per mile based on the 2013 
Internal Revenue Service standard mileage reimbursement rate for medical travel and the total 
repayment will not exceed $300.00.  If the patient does not complete the study for any reason 
during the first 3 months after randomization, the patient will be paid for the medical travel 
expense up to the time of study discontinuation.  
For patients randomized into Group B who are receiving Tacrolimus or Cyclosporin and 
Mycophenolic acid medications will not receive any payment or compensation for being in this 
research study because they may continue to have medication blood levels checked at the local 
laboratory with blood level results faxed to Dr. Kadry’s office
15.0
Drugs, Biologics, or Devices
Everolimus (Zortress)
IND# 113882
0.25mg-0078-0417-20
0.5mg-0078-0414-20
0.75mg-0078-0415-20
Investigational Drug Service Pharmacy stores & dispenses investigational item
16.0
Records and Study Monitoring-
Primary monitoring of the study will be performed by the study team, who will review accrual, adverse 
events, and dose limiting toxicities on a real-time basis.  Cumulative adverse events and study toxicities 
will be reviewed weekly.  The study team will make decisions regarding dose escalation, cessation of 
accrual, and whether stopping rules have been reached.  If stopping rules have been reached, this will be 
communicated to the IRB immediately
17.0
Facilities
Penn State Hershey Medical Center:  at the UPC Surgery Clinic facilities & hospital inpatient area if 
patient is hospitalized.
  
18.0
References
[1]
Burra P, Senzolo M, Masier A, Prestele H, Jones R, Samuel D, et al. Factors influencing 
renal function after liver transplantation. Results from the MOST, an international observational 
study. Dig Liver Dis. 2008 Nov 27.
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 17 of 18
[2]
Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. End-stage renal 
disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based 
immunotherapy: risk of development and treatment. Transplantation. 2001 Dec 27;72(12):1934-
9.
[3]
Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal 
failure after transplantation of a nonrenal organ. The New England journal of medicine. 2003 Sep 
4;349(10):931-40.
[4]
Velidedeoglu E, Bloom RD, Crawford MD, Desai NM, Campos L, Abt PL, et al. Early 
kidney dysfunction post liver transplantation predicts late chronic kidney disease. Transplantation. 
2004 Feb 27;77(4):553-6.
[5]
Wadei HM, Geiger XJ, Cortese C, Mai ML, Kramer DJ, Rosser BG, et al. Kidney 
allocation to liver transplant candidates with renal failure of undetermined etiology: role of 
percutaneous renal biopsy. Am J Transplant. 2008 Dec;8(12):2618-26.
[6]
Randhawa PS, Shapiro R. Chronic renal failure after liver transplantation. Am J Transplant. 
2005 May;5(5):967-8.
[7]
McCauley J, Van Thiel DH, Starzl TE, Puschett JB. Acute and chronic renal failure in liver 
transplantation. Nephron. 1990;55(2):121-8.
[8]
Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure 
following liver transplantation: a retrospective analysis. Transplantation. 1998 Jul 15;66(1):59-66.
[9]
Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al. Delayed 
introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' 
study. Am J Transplant. 2009 Feb;9(2):327-36.
[10]
Chapman TM, Perry CM. Everolimus. Drugs. 2004;64(8):861-72; discussion 73-4.
[11]
Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, et al. Safety, 
tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month 
results. Liver Transpl. 2006 Nov;12(11):1640-8.
[12]
Nashan B. Early clinical experience with a novel rapamycin derivative. Therapeutic drug 
monitoring. 2002 Feb;24(1):53-8.
[13]
Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, et al. 
Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation 
demonstrates its effectiveness. Transplantation. 2008 Mar 27;85(6):821-6.
[14]
Everson GT. Everolimus and mTOR inhibitors in liver transplantation: opening the "box". 
Liver Transpl. 2006 Nov;12(11):1571-3.
[15]
De Simone P, Carrai P, Precisi A, Petruccelli S, Baldoni L, Balzano E, et al. Conversion to 
everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on 
renal function. Transpl Int. 2009 Mar;22(3):279-86.
[16]
Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows 
early cyclosporine withdrawal in renal transplantation resulting in improved renal function and 
lower blood pressure. Transplantation. 2001 Sep 15;72(5):777-86.
PRAMS00038115
Approval: 1/7/2020

Protocol
IRB # 38115
                  
Version: December 28, 2018
Amendment 6Page 18 of 18
[17]
Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, et al. Early 
cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival 
and renal function at 48 months after transplantation. Transpl Int. 2005 Jan;18(1):22-8.
[18]
Ekberg H. Calcineurin inhibitor sparing in renal transplantation. Transplantation. 2008 Sep 
27;86(6):761-7.
[19]
Baboolal K. A phase III prospective, randomized study to evaluate concentration-
controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months 
in de novo renal allograft recipients. Transplantation. 2003 Apr 27;75(8):1404-8.
[20]
Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus 
and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic 
review and meta-analysis of randomized trials. Transplantation. 2006 May 15;81(9):1234-48.
[21]
Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, 
et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant 
recipients. The New England journal of medicine. 2003 Aug 28;349(9):847-58.
[22]
Levy GA, Grant D, Paradis K, Campestrini J, Smith T, Kovarik JM. Pharmacokinetics and 
tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. 
Transplantation. 2001 Jan 15;71(1):160-3.
[23]
Gomez-Camarero J, Salcedo M, Rincon D, Lo Iacono O, Ripoll C, Hernando A, et al. Use 
of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. 
Transplantation. 2007 Sep 27;84(6):786-91.
[24]
Yu SF, Wu LH, Zheng SS. Genetic factors for individual administration of 
immunosuppressants in organ transplantation. Hepatobiliary Pancreat Dis Int. 2006 Aug;5(3):337-
44.
[25]
Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: 
an example from a randomized trial. Statistics in medicine. 1996 Jul 15;15(13):1447-58.
[26]
Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an application 
of Fieller's theorem. Health economics. 1996 Jul-Aug;5(4):297-305.
[27]
Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its 
bootstraps: a non-parametric approach to confidence interval estimation. Health economics. 1997 
Jul-Aug;6(4):327-40.
[28]
Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness 
acceptability curves. Health economics. 2000 Oct;9(7):623-30.
[29]
Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver 
transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl. 2003 
Oct;9(10):1079-85.
PRAMS00038115
Approval: 1/7/2020